| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 87 | 2024 | 7784 | 4.510 |
Why?
|
| Lung Neoplasms | 69 | 2024 | 11758 | 3.360 |
Why?
|
| Diagnostic Imaging | 25 | 2024 | 1178 | 3.210 |
Why?
|
| Positron-Emission Tomography | 39 | 2024 | 2198 | 2.860 |
Why?
|
| Pleural Neoplasms | 13 | 2023 | 484 | 2.620 |
Why?
|
| Pericardium | 7 | 2024 | 149 | 2.370 |
Why?
|
| Mediastinal Neoplasms | 8 | 2022 | 429 | 2.320 |
Why?
|
| Thoracic Neoplasms | 8 | 2021 | 347 | 2.110 |
Why?
|
| Mediastinum | 11 | 2022 | 278 | 1.950 |
Why?
|
| Mesothelioma | 10 | 2022 | 558 | 1.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 31 | 2024 | 5516 | 1.630 |
Why?
|
| Fluorodeoxyglucose F18 | 26 | 2024 | 1260 | 1.560 |
Why?
|
| Positron Emission Tomography Computed Tomography | 14 | 2024 | 878 | 1.560 |
Why?
|
| Thymus Neoplasms | 9 | 2024 | 420 | 1.460 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2021 | 125 | 1.360 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 13975 | 1.360 |
Why?
|
| Multimodal Imaging | 8 | 2015 | 551 | 1.360 |
Why?
|
| Thorax | 9 | 2022 | 230 | 1.310 |
Why?
|
| Tomography, Emission-Computed | 10 | 2011 | 336 | 1.190 |
Why?
|
| Lymphadenopathy | 3 | 2022 | 94 | 1.040 |
Why?
|
| Radiopharmaceuticals | 21 | 2024 | 1338 | 1.010 |
Why?
|
| Radiography, Thoracic | 14 | 2019 | 473 | 0.950 |
Why?
|
| Lung | 27 | 2022 | 3268 | 0.920 |
Why?
|
| Mediastinal Diseases | 2 | 2022 | 58 | 0.900 |
Why?
|
| Pulmonary Embolism | 6 | 2022 | 333 | 0.850 |
Why?
|
| Diagnostic Errors | 7 | 2021 | 532 | 0.830 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2021 | 593 | 0.830 |
Why?
|
| Diagnosis, Differential | 26 | 2019 | 4902 | 0.810 |
Why?
|
| Fat Necrosis | 1 | 2022 | 59 | 0.790 |
Why?
|
| Humans | 166 | 2024 | 271076 | 0.780 |
Why?
|
| Lung Diseases | 6 | 2024 | 751 | 0.760 |
Why?
|
| Thymoma | 5 | 2024 | 253 | 0.650 |
Why?
|
| Heart Neoplasms | 3 | 2018 | 216 | 0.600 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 324 | 0.590 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 1325 | 0.590 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 373 | 0.580 |
Why?
|
| Neuroblastoma | 1 | 2022 | 701 | 0.570 |
Why?
|
| Radiology Information Systems | 1 | 2018 | 118 | 0.560 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 83 | 0.560 |
Why?
|
| Bone Cements | 2 | 2015 | 49 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2024 | 7950 | 0.530 |
Why?
|
| Mass Screening | 4 | 2022 | 1554 | 0.520 |
Why?
|
| Radiotherapy | 5 | 2017 | 1858 | 0.520 |
Why?
|
| Heart Diseases | 1 | 2022 | 737 | 0.510 |
Why?
|
| Thoracic Diseases | 1 | 2015 | 30 | 0.490 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 130 | 0.490 |
Why?
|
| Artifacts | 10 | 2021 | 537 | 0.480 |
Why?
|
| Tomography, Spiral Computed | 3 | 2010 | 128 | 0.460 |
Why?
|
| Immunotherapy | 8 | 2024 | 3533 | 0.460 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2024 | 523 | 0.420 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 126 | 0.420 |
Why?
|
| False Positive Reactions | 8 | 2015 | 373 | 0.410 |
Why?
|
| Contrast Media | 12 | 2015 | 1510 | 0.410 |
Why?
|
| Adipose Tissue, Brown | 3 | 2013 | 117 | 0.390 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 14678 | 0.390 |
Why?
|
| Dyspnea | 1 | 2015 | 419 | 0.390 |
Why?
|
| Lymphatic Metastasis | 12 | 2019 | 4968 | 0.390 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 32 | 0.380 |
Why?
|
| Multidetector Computed Tomography | 3 | 2024 | 148 | 0.370 |
Why?
|
| Pneumonia | 5 | 2022 | 796 | 0.360 |
Why?
|
| Pleura | 3 | 2022 | 129 | 0.350 |
Why?
|
| Pulmonary Artery | 3 | 2020 | 520 | 0.330 |
Why?
|
| Sensitivity and Specificity | 15 | 2019 | 5183 | 0.300 |
Why?
|
| Hemorrhage | 2 | 2022 | 742 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2009 | 1708 | 0.280 |
Why?
|
| Esophageal Neoplasms | 8 | 2022 | 3236 | 0.280 |
Why?
|
| Middle Aged | 53 | 2022 | 90070 | 0.280 |
Why?
|
| Vocal Cord Paralysis | 2 | 2006 | 93 | 0.280 |
Why?
|
| Male | 61 | 2022 | 128555 | 0.270 |
Why?
|
| Digestive System Diseases | 2 | 2018 | 39 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2017 | 5568 | 0.260 |
Why?
|
| Adult | 45 | 2022 | 81614 | 0.260 |
Why?
|
| Mycobacterium avium | 1 | 2005 | 21 | 0.260 |
Why?
|
| Lung Diseases, Fungal | 3 | 2015 | 133 | 0.260 |
Why?
|
| Mycobacterium avium Complex | 1 | 2005 | 33 | 0.260 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2005 | 36 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 427 | 0.250 |
Why?
|
| Aged | 46 | 2021 | 73177 | 0.240 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2017 | 59 | 0.240 |
Why?
|
| Histoplasma | 1 | 2004 | 35 | 0.240 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2004 | 20 | 0.240 |
Why?
|
| Female | 59 | 2022 | 148608 | 0.240 |
Why?
|
| Lymphadenitis | 1 | 2004 | 42 | 0.240 |
Why?
|
| Radiation Injuries | 4 | 2021 | 1472 | 0.240 |
Why?
|
| Parietal Lobe | 1 | 2004 | 71 | 0.240 |
Why?
|
| Pulmonologists | 1 | 2024 | 12 | 0.230 |
Why?
|
| Histoplasmosis | 1 | 2004 | 81 | 0.230 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1955 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 4 | 2017 | 4124 | 0.230 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 408 | 0.230 |
Why?
|
| Radiography | 8 | 2018 | 1989 | 0.230 |
Why?
|
| Epilepsy, Generalized | 1 | 2004 | 73 | 0.230 |
Why?
|
| Polytetrafluoroethylene | 1 | 2004 | 110 | 0.230 |
Why?
|
| Neoplasms | 11 | 2024 | 15838 | 0.210 |
Why?
|
| Postoperative Complications | 5 | 2021 | 5690 | 0.210 |
Why?
|
| Radiologists | 3 | 2022 | 177 | 0.210 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 172 | 0.200 |
Why?
|
| Image Enhancement | 2 | 2007 | 555 | 0.200 |
Why?
|
| Hemosiderin | 1 | 2021 | 6 | 0.200 |
Why?
|
| Methemoglobin | 1 | 2021 | 9 | 0.200 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2021 | 39 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2017 | 1269 | 0.200 |
Why?
|
| Incidental Findings | 2 | 2018 | 280 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2282 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 605 | 0.190 |
Why?
|
| ErbB Receptors | 3 | 2018 | 2379 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 532 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2021 | 248 | 0.180 |
Why?
|
| Bevacizumab | 4 | 2018 | 959 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 156 | 0.170 |
Why?
|
| Angiography | 2 | 2022 | 344 | 0.170 |
Why?
|
| Fibroma | 1 | 2000 | 88 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 410 | 0.170 |
Why?
|
| Airway Obstruction | 1 | 2021 | 272 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2005 | 617 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 396 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 291 | 0.150 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 57 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 397 | 0.150 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 72 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 357 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 1998 | 74 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 630 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 94 | 0.140 |
Why?
|
| Vascular Diseases | 2 | 2016 | 244 | 0.140 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2016 | 14 | 0.140 |
Why?
|
| Legionellosis | 1 | 2016 | 18 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 238 | 0.140 |
Why?
|
| Glucose-6-Phosphate | 2 | 2006 | 13 | 0.140 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2016 | 26 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2015 | 240 | 0.140 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2016 | 33 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2022 | 6982 | 0.130 |
Why?
|
| Lymph Nodes | 4 | 2018 | 3067 | 0.130 |
Why?
|
| Adenocarcinoma | 6 | 2014 | 7938 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 732 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 95 | 0.130 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 30937 | 0.130 |
Why?
|
| Retrospective Studies | 22 | 2023 | 39710 | 0.130 |
Why?
|
| Hyperparathyroidism | 2 | 2006 | 105 | 0.130 |
Why?
|
| Esophagus | 2 | 2018 | 563 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 223 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 135 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2399 | 0.120 |
Why?
|
| Pneumonectomy | 2 | 2018 | 863 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 421 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2007 | 1312 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2015 | 57 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 751 | 0.120 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Muscle, Striated | 1 | 2013 | 13 | 0.110 |
Why?
|
| Urologic Diseases | 1 | 2014 | 84 | 0.110 |
Why?
|
| Heart | 3 | 2018 | 1211 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 994 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2023 | 1370 | 0.110 |
Why?
|
| Warfarin | 1 | 2015 | 152 | 0.110 |
Why?
|
| Empyema | 1 | 2013 | 37 | 0.110 |
Why?
|
| Respiratory Tract Fistula | 1 | 2013 | 34 | 0.110 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 37 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 80 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2013 | 58 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1859 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 338 | 0.110 |
Why?
|
| Research Design | 1 | 2010 | 1568 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1379 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2018 | 5324 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 908 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2013 | 218 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1838 | 0.100 |
Why?
|
| United States | 4 | 2022 | 15989 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 2007 | 1437 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 17835 | 0.100 |
Why?
|
| Smoking | 1 | 2010 | 2425 | 0.100 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 15256 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 936 | 0.100 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 236 | 0.090 |
Why?
|
| Carcinoma | 1 | 2022 | 2627 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 113 | 0.090 |
Why?
|
| Pneumonia, Lipid | 1 | 2010 | 5 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2010 | 51 | 0.090 |
Why?
|
| Thyroid Gland | 2 | 2018 | 372 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2021 | 33833 | 0.090 |
Why?
|
| Prognosis | 8 | 2022 | 22463 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 9042 | 0.090 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2010 | 49 | 0.090 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2009 | 22 | 0.090 |
Why?
|
| Quality Control | 2 | 2017 | 466 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 378 | 0.090 |
Why?
|
| Iatrogenic Disease | 2 | 2014 | 198 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2017 | 1201 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 6165 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 4984 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2015 | 784 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 74 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Zygomycosis | 1 | 2008 | 30 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4956 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2006 | 734 | 0.080 |
Why?
|
| Fusarium | 1 | 2008 | 57 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2474 | 0.080 |
Why?
|
| Subtraction Technique | 2 | 2006 | 145 | 0.080 |
Why?
|
| Survival Rate | 6 | 2013 | 12519 | 0.080 |
Why?
|
| Parathyroidectomy | 2 | 2006 | 207 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 1604 | 0.070 |
Why?
|
| Adolescent | 6 | 2018 | 32595 | 0.070 |
Why?
|
| Pyridines | 2 | 2017 | 1312 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 619 | 0.070 |
Why?
|
| Observer Variation | 4 | 2017 | 723 | 0.070 |
Why?
|
| Respiration | 2 | 2006 | 465 | 0.070 |
Why?
|
| Liver | 2 | 2022 | 3127 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 90 | 0.070 |
Why?
|
| Hyperventilation | 1 | 2006 | 20 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 748 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 49 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2006 | 27 | 0.070 |
Why?
|
| Pleurodesis | 1 | 2006 | 70 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 97 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 81 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 68 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 79 | 0.060 |
Why?
|
| Proton Therapy | 1 | 2016 | 1638 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10349 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 16592 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 236 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2004 | 24 | 0.060 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2012 | 113 | 0.060 |
Why?
|
| Kyphosis | 1 | 2004 | 45 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2006 | 420 | 0.060 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2004 | 64 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 186 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2020 | 293 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 72 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2023 | 13353 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 166 | 0.060 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2005 | 143 | 0.060 |
Why?
|
| Mass Chest X-Ray | 1 | 2003 | 4 | 0.060 |
Why?
|
| Piperidines | 1 | 2009 | 1089 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 721 | 0.050 |
Why?
|
| Spine | 1 | 2004 | 311 | 0.050 |
Why?
|
| Reference Values | 1 | 2005 | 1156 | 0.050 |
Why?
|
| Biopsy, Needle | 3 | 2018 | 1403 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2005 | 703 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 337 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1326 | 0.050 |
Why?
|
| Public Opinion | 1 | 2022 | 77 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 66 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2009 | 1934 | 0.050 |
Why?
|
| Thyroiditis | 1 | 2020 | 19 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1516 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2007 | 881 | 0.050 |
Why?
|
| Biopsy | 3 | 2014 | 3555 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 2426 | 0.050 |
Why?
|
| Myocardium | 1 | 2006 | 1248 | 0.050 |
Why?
|
| Indoles | 1 | 2006 | 1035 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 342 | 0.050 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 70 | 0.040 |
Why?
|
| Pericarditis | 1 | 2020 | 65 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1522 | 0.040 |
Why?
|
| Hepatitis | 1 | 2020 | 94 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2005 | 1288 | 0.040 |
Why?
|
| Mouth | 1 | 2021 | 124 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2010 | 182 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2007 | 1318 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2020 | 114 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 4067 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 234 | 0.040 |
Why?
|
| Encephalitis | 1 | 2020 | 155 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2010 | 315 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 671 | 0.040 |
Why?
|
| Pneumothorax | 1 | 2000 | 165 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 381 | 0.040 |
Why?
|
| Myocarditis | 1 | 2020 | 195 | 0.040 |
Why?
|
| Colitis, Ischemic | 1 | 1998 | 4 | 0.040 |
Why?
|
| Diverticulitis, Colonic | 1 | 1998 | 12 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7816 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2434 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 2266 | 0.040 |
Why?
|
| Prevalence | 2 | 2018 | 3423 | 0.040 |
Why?
|
| Liver Diseases | 2 | 2014 | 606 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15855 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 344 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2000 | 365 | 0.040 |
Why?
|
| Quinazolines | 2 | 2017 | 953 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2471 | 0.040 |
Why?
|
| Ascites | 1 | 1998 | 217 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2004 | 3138 | 0.040 |
Why?
|
| Legionella | 1 | 2016 | 18 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 744 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2004 | 2099 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2023 | 2851 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1043 | 0.030 |
Why?
|
| Ireland | 1 | 2015 | 31 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1734 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2346 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 148 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 255 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2018 | 9309 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5411 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 327 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1998 | 322 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 2016 | 159 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 526 | 0.030 |
Why?
|
| Child | 3 | 2022 | 30421 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2007 | 5188 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 1894 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1222 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2014 | 60 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 5087 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 16981 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 126 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 5112 | 0.030 |
Why?
|
| Stroke | 1 | 2021 | 1092 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 3866 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4982 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 348 | 0.030 |
Why?
|
| Ileus | 1 | 2012 | 29 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 384 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 916 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2009 | 1740 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 472 | 0.020 |
Why?
|
| Esophagectomy | 2 | 2007 | 946 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1840 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1062 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 6837 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2984 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1330 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 1439 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 112 | 0.020 |
Why?
|
| Respiratory Aspiration | 1 | 2010 | 31 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 3543 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3909 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4840 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2012 | 343 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5524 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 746 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1820 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1542 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 2029 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5898 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 749 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 96 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2009 | 199 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3398 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2006 | 35 | 0.020 |
Why?
|
| Back | 1 | 2006 | 49 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 169 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2006 | 125 | 0.020 |
Why?
|
| Biological Products | 1 | 2010 | 316 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2164 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 698 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 22062 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 559 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 658 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2006 | 137 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 1322 | 0.020 |
Why?
|
| Disease Progression | 2 | 2009 | 6896 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4885 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 340 | 0.020 |
Why?
|
| Bronchography | 1 | 2004 | 24 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 187 | 0.020 |
Why?
|
| Heart Failure | 1 | 1998 | 2498 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 42 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2006 | 309 | 0.010 |
Why?
|
| Thoracoscopy | 1 | 2005 | 103 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2010 | 2621 | 0.010 |
Why?
|
| Thymectomy | 1 | 2004 | 80 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 181 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2005 | 336 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 2034 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 704 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 875 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 586 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 1568 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 713 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4332 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1621 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 991 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3972 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 1379 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 605 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2000 | 44 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 47 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 879 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6249 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 1548 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 3082 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2508 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 826 | 0.010 |
Why?
|
| Catheterization | 1 | 2000 | 423 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10250 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 2493 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3236 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 605 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2648 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2002 | 920 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2002 | 949 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 4511 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 9078 | 0.010 |
Why?
|